Product Images Teriflunomide

This is a clinical study evaluating the efficacy of different doses of teriflunomide, a drug used for treating relapsing-remitting multiple sclerosis (RRMS), compared to a placebo. The study lasted for 108 weeks and consisted of a total of 873 patients taking either a placebo or one of two doses of teriflunomide (7 mg or 14 mg). The number of patients at risk was recorded at different time points during the study, and statistical analysis showed that the 14 mg dose of teriflunomide was significantly better than the placebo for treating RRMS.*

This seems to be a table presenting disability progression data for three different treatments (Placebo, 7 mg Terifunomide and 14 mg Terilunomide). The data shows the percentage of sustained disability progression for 12 weeks for each treatment. There are also graphs displaying the number of patients at risk over the weeks, for each treatment. No further context or explanation is available.*

This is a description for Teriflunomide tablets, with a recommended usual dosage of one tablet taken orally once daily. The tablets contain 7 mg of Terifunomide. They can be taken with or without food and should be stored between 20°C-25°C. The package is child-resistant with a warning to keep out of reach of children. The medication guide is available at '2ydususa comimeaguides' or can be called at 1-877-9838775. The manufacturer is Zydus Lifesciences Ltd., located in Bhmesabad, and the distributor is Zydus Pharmaceuticals USA Inc., located in Penvingon.*